On May 6, 2026, the Centers for Medicare and Medicaid Services (CMS) announced a new program that will give eligible Medicare Part D beneficiaries access to certain glucagon-like peptide-1 (GLP-1) medications for $50 per month starting July 1, 2026.[1] The program runs through December 31, 2027 under a broader pilot called the BALANCE Model.[2]
That single announcement changes the math on one of the most-prescribed drug categories in primary care. For the tens of millions of Americans on Medicare, the price of a branded GLP-1 like Ozempic or Wegovy is about to drop from roughly $1,000 per month at list to $50.[1][3]
It also changes what a concierge or direct primary care doctor is actually worth on a GLP-1 case. For the last three years, the main value proposition of a concierge or telehealth GLP-1 program was access: sourcing the drug during shortages, navigating prior authorization, or offering a compounded version while supply caught up. As the access problem goes away, the value migrates somewhere else. It migrates into management.
This piece walks through what that shift looks like in 2026, what management actually involves, and what to ask a concierge or direct primary care (DPC) doctor before signing up.
What Just Changed on GLP-1 Access
Three forces are collapsing the price wall on GLP-1 medications at the same time.
1. Medicare's $50 Bridge. Starting July 1, 2026, eligible Medicare Part D beneficiaries will be able to access certain GLP-1 medications for $50 per month under the new CMS demonstration.[1] Roughly 50 million Americans are enrolled in Medicare Part D today,[3] which makes this the single largest price-floor reset the category has seen.
2. Branded direct-to-consumer pricing. Eli Lilly began selling Zepbound through its direct-to-consumer pharmacy (LillyDirect) in single-dose vials in 2024, with self-pay prices that often land in the $349 to $499 per month range, well below the brand-pen price.[4] Novo Nordisk and Hims and Hers have been moving toward branded distribution arrangements that pull cash-pay semaglutide prices down in a similar direction.[5]
3. The compounded GLP-1 channel is winding down. The Food and Drug Administration (FDA) has removed both semaglutide and tirzepatide from its drug shortage list and has been narrowing the legal compounding pathway that briefly supported sub-$300-per-month telehealth subscriptions.[6] That category is being absorbed into branded distribution rather than competing with it.
The combined effect is straightforward. The cash-pay price of a GLP-1 used to be the gating constraint on who could try one. By the end of 2026, it will not be the constraint for most patients with any coverage at all.
Why Access Was a Bad Moat
Concierge and telehealth clinics that built their GLP-1 business around access were building on a temporary advantage. The shortages were temporary, the legal compounding window was temporary, and the prior-authorization complexity was always going to soften as payers built standard workflows around the category.
What none of those clinics built was a deep medical relationship with the patient. The model assumed the patient would start the drug, fill the prescription month after month, and self-titrate based on a chat thread. That works well during the dose-find phase and breaks down everywhere else.
The breakdown shows up in the dropout numbers. A 2024 Prime Therapeutics analysis found that about 47% of patients who started a GLP-1 for weight loss had stopped within one year, with roughly a third stopping inside the first three months.[7] Some of that is intentional weight-goal completion. Most of it is not. Side effects, supply gaps, insurance changes, and a lack of medical follow-up account for the majority of dropouts.[7]
A patient who started Ozempic on a chat-based platform in 2024 and quietly stopped after seven months because the nausea got worse during a dose increase is the rule, not the exception. That patient never got the management they needed.
The Five Things "Management" Actually Means
Long-term GLP-1 care is a real medical job, not a refill loop. Concretely, it involves five things that need physician time and attention.
1. Repeat labs at the right intervals and actually read them. Baseline labs before starting a GLP-1 typically include hemoglobin A1c (a 3-month blood sugar average), a fasting lipid panel, kidney function (creatinine and estimated glomerular filtration rate), liver enzymes, and thyroid function. Most clinicians repeat the core set every 3 to 6 months during the dose-find phase and every 6 to 12 months thereafter. A doctor who orders labs and never sits down with you to walk through them is not managing the case.
2. Watch for muscle loss. Body-composition data from the major obesity trials show that roughly 25 to 40% of the total weight lost on a GLP-1 comes from lean tissue, depending on the drug and the patient's protein intake.[8][9] A patient losing 50 pounds in a year may be losing 15 to 20 pounds of lean mass without anyone telling them. The countermeasures are concrete: clinicians studying GLP-1 drugs typically target around 1.2 to 1.6 grams of protein per kilogram of body weight per day, plus two or three resistance-training sessions per week. Those are the kind of details that require a real conversation, not a chatbot.
3. Manage side effects that show up after the dose-find phase. Nausea, vomiting, constipation, and reflux usually peak during dose escalation and settle as the patient stabilizes. A smaller set of issues tends to show up later: gallstones (more common during rapid weight loss), pancreatitis, gastroparesis-like symptoms, and resting heart rate increases of about 5 to 7 beats per minute documented in the trials of the newer triple-receptor candidates.[8] Most of these need physical examination, imaging, or specialist referral.
4. Adjust the rest of the medication list. GLP-1 drugs slow gastric emptying, which changes how the body absorbs oral medications. The list of commonly affected drugs includes oral birth control, levothyroxine (the thyroid hormone replacement most adults with hypothyroidism take), warfarin, and several antibiotics. Patients with type 2 diabetes who start a GLP-1 often need to step down their insulin or sulfonylureas to avoid low blood sugar. None of that gets caught unless someone is reviewing the full medication list each visit.
5. Plan the off-ramp. Published evidence from the STEP-1 trial suggests that patients who stop semaglutide without a structured maintenance plan regain a large share of the lost weight within a year.[9] The realistic options are: lower-dose maintenance held indefinitely, a structured taper with concurrent lifestyle reinforcement, or a transition to a different drug class. Each requires a physician who has the time to think through the case.
A traditional primary care visit is too short to do most of this work. Researchers analyzing 21 million primary care visits using the athenahealth platform found the average visit length was about 18 minutes,[10] and direct observation studies have found that actual face-to-face physician time inside that visit is closer to 7 minutes.[10] You cannot run a complete GLP-1 management plan in 7 minutes.
Why the Concierge and DPC Models Fit the Management Phase
Concierge medicine and direct primary care use the same lever: a smaller patient panel that buys the doctor more time per patient.
Model | Panel size per doctor | Visit length | Annual cost to patient |
|---|---|---|---|
Concierge medicine | Under 300 patients | 30 to 60+ minutes | $3,000 to over $40,000 |
Direct primary care (DPC) | Up to 800 patients | 30 to 60 minutes | $600 to $2,400 ($50 to $200 per month) |
Traditional primary care | 2,000 to 2,500 patients | 10 to 15 minutes | Covered by insurance |
A 2020 Society of Actuaries and Milliman evaluation of direct primary care found that DPC patients used the emergency room about 40.51% less often than matched traditional-insurance patients, and total cost of care was lower despite the upfront membership fee.[11] That gap follows from having a doctor who can be reached when something feels off, rather than a triage line that defaults to "go to the ER."
For a GLP-1 patient, that translates to specific things. A 45-minute visit to review six months of labs. A text-message reply when the dose increase is making nausea unmanageable. A real conversation about whether to hold at the current dose or step up. A plan for year three rather than a refill loop.
The patient who gets the most out of moving to a concierge or DPC model on a GLP-1 is usually the patient who already takes three or more medications, has more than one chronic condition, or is past the dose-find phase and trying to decide what year-two looks like.
What This Looks Like Across Pricing Tiers
NextMD groups concierge practices into three pricing tiers, and the GLP-1 management experience differs at each one.
Entry-level concierge ($2,500 to $5,000 per year). Practices like The Cove Concierge Medicine in Castle Rock, Colorado. Patients typically get same-week or same-day visits, a direct line to the physician, and the time needed to actually work a GLP-1 case across the year.
Premium concierge ($5,000 to $12,000 per year). Practices like WVL Synergy in Naples, Florida. Premium-tier practices often add in-house phlebotomy, body-composition scanning by dual-energy X-ray absorptiometry (DXA, a low-radiation imaging method that measures bone density, lean mass, and fat mass), and a longer initial intake. For a GLP-1 patient worried about muscle loss, the DXA scan moves from a nice-to-have to a real management tool.
Ultra-premium concierge ($15,000 and up, commonly over $40,000 per year). Practices like MD2 Madison Avenue in New York. At this tier, the practice often coordinates the entire metabolic and longevity workup, including specialist referrals, advanced imaging, and travel-ready medical support.
Direct primary care covers the lower end. A DPC membership at $75 to $150 per month buys the same panel-size dynamic without the higher per-year fee, and many DPC practices have built specific GLP-1 protocols because their employer clients have asked for them.
A Word on the "Is My Doctor Even a Doctor?" Question
The concierge and direct primary care category is growing, but it is growing in two directions at once. A December 2025 Health Affairs study found that the number of concierge and DPC clinicians grew from 3,935 in 2018 to 7,021 in 2023, an increase of 78.4%. Over the same period, the share of those clinicians who are physicians fell from 67.3% to 59.7%.[12] In other words, the category is adding nurse practitioner and physician assistant-led practices faster than it is adding physician-led ones.
For a patient managing a GLP-1, that distinction is medically relevant. Adjusting other prescription medications, reading labs across systems, and managing the post-stop transition are physician-level tasks. NextMD lists only practices that have at least one MD or DO physician. When you search for a concierge or DPC doctor on nextmd.ai, you are searching a physician-verified list.
What to Ask Before You Sign Up
If you are on a GLP-1, or are considering starting one, the right questions to ask a concierge or DPC practice before joining are concrete:
How many of your current patients are on a GLP-1?
Do you order body-composition scans or rely on weight alone to track progress?
What is your protocol for managing nausea during dose increases?
Do you have a written off-ramp plan, and how do you decide when a patient is ready?
Do you adjust other medications (insulin, oral contraceptives, thyroid hormone) when a patient starts a GLP-1?
How do I reach you between visits, and how fast do you usually respond?
A practice that can answer all six in a single intake call is set up to manage the year-two version of the case. A practice that hedges on three or four of them is mostly built around the start.
A Note From the Author
I am not a doctor. Nothing in this article should be considered medical advice.
This piece is a plain-language summary of publicly available CMS announcements, peer-reviewed clinical research, AI and industry data. Before starting, stopping, switching, or adjusting any prescription medication, including any drug in the GLP-1 or multi-receptor class, talk to a licensed physician who knows your medical history.
NextMD helps you find and compare concierge medicine and direct primary care practices across the United States. Browse practices by city, compare pricing, and find a doctor who has time for you at nextmd.ai/search.
Sources
Centers for Medicare and Medicaid Services. (2026, May 6). Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries. CMS Newsroom Press Release. Read on CMS.gov
Centers for Medicare and Medicaid Services. (2026). BALANCE Model. CMS Innovation Center. Read on CMS.gov
Kaiser Family Foundation. (2026). What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid. KFF Issue Brief. Read on KFF.org
Eli Lilly and Company. (2024–2026). LillyDirect Self-Pay Pricing for Zepbound Single-Dose Vials. Manufacturer direct-to-consumer pharmacy program. Read on LillyDirect.com Referenced for the $349 to $499 per month self-pay vial price range for Zepbound.
Hims and Hers Health, Inc. (2026). Investor and Press Coverage of Branded GLP-1 Distribution Arrangements. See company investor relations for current 10-Q and 10-K filings: Read on investors.hims.com. Referenced for the broader pattern of branded semaglutide distribution moving into direct-to-consumer telehealth channels in 2026.
U.S. Food and Drug Administration. (2023–2026). Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss. Drug Safety Information for Patients and Providers. Read on FDA.gov. Referenced for the FDA shortage-list updates and ongoing warnings on compounded GLP-1 products.
Prime Therapeutics. (2024). Real-World GLP-1 Persistence Among Patients Using GLP-1 Receptor Agonists for Weight Loss. Prime Therapeutics research report. See published GLP-1 discontinuation studies: Search on PubMed. Referenced for the discontinuation rate of approximately 47% within one year.
Jastreboff, A.M., Kaplan, L.M., Frias, J.P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M.L. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526. Read on NEJM. Referenced for the body-composition split and the resting heart rate increase observed at higher doses.
Wilding, J.P.H., Batterham, R.L., Calanna, S., Davies, M., Van Gaal, L.F., Lingvay, I., McGowan, B.M., Rosenstock, J., Tran, M.T.D., Wadden, T.A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R.F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 384(11), 989–1002. Read on NEJM. Referenced for the post-stop weight-regain finding in the STEP-1 extension.
Neprash, H.T., Everhart, A., McAlpine, D., Smith, L.B., Sheridan, B., & Cross, D.A. (2023). Measuring Primary Care Exam Length Using Electronic Health Record Data. Medical Care, 61(7), 414–422. Read on PubMed (PMID 37219072). Referenced for the 18-minute average visit length and the shorter observed face-to-face physician time.
Busch, F., Grzeskowiak, D., & Huth, E. (2020). Direct Primary Care: Evaluating a New Model of Delivery and Financing. Society of Actuaries / Milliman. Read the full report on SOA.org. Referenced for the 40.51% emergency room reduction in DPC patients.
Zhu, J.M., et al. (2025). Growth in Concierge and Direct Primary Care Practices and Clinicians in the United States, 2018–2023. Health Affairs. Read on Health Affairs. Referenced for the 78.4% clinician growth and the decline in the physician share from 67.3% to 59.7%.